Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 16 full-time employees. The firm is focused on developing a therapeutic product for the treatment of migraine. The Company’s product candidate STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate (DHE), which can be self-administered with a proprietary pre-filled, single-use, nasal delivery device.